Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year Low - Should You Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s share price hit a new 52-week low on Monday . The stock traded as low as $13.46 and last traded at $13.55, with a volume of 20362 shares trading hands. The stock had previously closed at $14.38.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on BCAX shares. Cantor Fitzgerald began coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an "overweight" rating on the stock. Stifel Nicolaus began coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a "buy" rating and a $47.00 price target on the stock. Morgan Stanley assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an "overweight" rating and a $35.00 price objective for the company. Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a "buy" rating and a $48.00 target price on the stock. Finally, TD Cowen assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Bicara Therapeutics currently has an average rating of "Buy" and an average target price of $43.00.

Bicara Therapeutics Stock Performance

The company's 50-day simple moving average is $19.04.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). On average, equities analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Barclays PLC bought a new stake in Bicara Therapeutics during the third quarter worth $255,000. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at about $358,000. Geode Capital Management LLC acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at about $1,239,000. Jane Street Group LLC bought a new position in Bicara Therapeutics during the third quarter worth about $309,000. Finally, Wellington Management Group LLP bought a new position in Bicara Therapeutics during the third quarter worth about $19,458,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.